HUTCHMED (China) Limited announced today, November 5, 2025, the completion of patient enrollment in its global Phase III clinical trial—known as SAFFRON—evaluating the oral combination of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) in the treatment of patients with epidermal growth factor receptor (EGFR)-mutated, MET-overexpressed and/or amplified, locally advanced or metastatic non-small cell lung cancer (NSCLC) who have experienced progression following prior EGFR tyrosine kinase inhibitor (TKI) therapy. The last patient was randomized on October 31, 2025, marking a significant recruitment milestone relevant to the Asia-Pacific’s biopharmaceutical clinical development and regulatory landscape.

This combination regimen is positioned as a promising chemotherapy-free, fully oral therapeutic option for advanced NSCLC, following recent approval in China (June 2025) based on the pivotal SACHI randomized Phase III trial. ORPATHYS®, a potent and selective MET inhibitor co-developed by HUTCHMED and AstraZeneca, is commercialized by AstraZeneca across Asia. TAGRISSO® is a third-generation irreversible EGFR inhibitor by AstraZeneca that has established itself as a backbone of advanced EGFR-mutant NSCLC management globally, with particular relevance in Asian populations where EGFR mutations are prevalent among lung cancer patients.

The SAFFRON trial is structured as a global, multicenter, open-label, randomized Phase III study, tracking both efficacy and safety outcomes for patients whose disease has progressed despite first-line EGFR TKI. The trial is expected to generate pivotal clinical data to support further regulatory submissions throughout Asia-Pacific and beyond, with readouts anticipated to impact regional treatment guidelines and accelerated drug access pathways.

The robust enrollment and multinational scope of SAFFRON underscore the increasing clinical trial sophistication in Asia, as sponsors leverage regional sites and patient pools to meet accelerated timelines and regulatory expectations for innovative oral oncology regimens. Asian clinical sites are playing a prominent role in ensuring diverse patient representation, bolstering scientific rigor, and supporting post-SACHI regulatory filings for expanded label indications throughout major markets such as China, Japan, Korea, and ASEAN.

This milestone exemplifies the broader shift toward targeted, biomarker-driven therapy in the Asian NSCLC landscape, as pharma companies prioritize scalable, oral, and biologic-free regimens to address population-specific genomic characteristics and healthcare system requirements. It also reflects the growing dominance of local and regional sponsors in leading late-stage combination studies, often in partnership with multinational pharma companies looking to accelerate access and convergence of Asian real-world evidence, regulatory data, and post-marketing commitments.

For pharmaceutical executives, clinical research leaders, and regulatory teams in Asia, SAFFRON’s progress signals new benchmarking for regional operational excellence, cross-border partnership in global trial deployment, and evolving regulatory paradigms for combination precision oncology. The study also provides a strategic case for leveraging Asia-Pacific clinical ecosystems for pivotal development programs and expedited patient access to next-generation oral targeted therapies in high-burden indications.